Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease.

Journal of neurology - 1 Apr 2021

Thaler Avner, Omer Nurit, Giladi Nir, Gurevich Tanya, Bar-Shira Anat, Gana-Weisz Mali, Goldstein Orly, Kestenbaum Meir, Cedarbaum Jesse M, Orr-Urtreger Avi, Shenhar-Tsarfaty Shani, Mirelman Anat

Abstract excerpt

BACKGROUND: The phenotype of Parkinson's disease (PD) is variable with mutations in genes such as LRRK2 and GBA explaining part of this heterogeneity. Additional genetic and environmental factors contribute to disease variability. OBJECTIVE: To assess the association between biochemical markers, PD severity and probability score for prodromal PD, among GBA and LRRK2 mutation carriers. METHODS: Levels of uric...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Glucosylceramidase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterozygote

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Mutation

Share to Parkinson Disease

Source

Identifiers

PMID: 33388928
DOI: 10.1007/s00415-020-10325-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease.PMID 33388928Read ↗

Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach.Semantic proximity Read ↗

The Impact of 90 Parkinson's Disease-Risk Single Nucleotide Polymorphisms on Urinary Bis(monoacylglycerol)phosphate Levels in the Prodromal and PD Cohorts.Semantic proximity Read ↗

Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson diseaseSemantic proximity Read ↗

Update of the MDS research criteria for prodromal Parkinson's diseaseSemantic proximity Read ↗

Apathy: an underestimated feature in GBA and LRRK2 non-manifesting mutation carriersSemantic proximity Read ↗

Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.Semantic proximity Read ↗

β-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters.Semantic proximity Read ↗

Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlationsSemantic proximity Read ↗

Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.Semantic proximity Read ↗

Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers.Semantic proximity Read ↗

Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.Semantic proximity Read ↗

Biomarkers of LRRK2 and lysosomal dysfunction in Progressive Supranuclear PalsySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.